Exelixis
EXEL
#1725
Rank
S$12.88 B
Marketcap
$45.11
Share price
-1.16%
Change (1 day)
44.84%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Earnings for Exelixis (EXEL)

Earnings in 2024 (TTM): S$0.79 Billion

According to Exelixis's latest financial reports the company's current earnings are S$2.08 Billion. In 2023 the company made an earning of S$0.34 Billion, an increase over its 2022 earnings that were of S$0.31 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Exelixis from 2000 to 2024

Annual earnings

Year Earnings Change
2024 (TTM) S$0.79 B128.67%
2023 S$0.34 B9.89%
2022 S$0.31 B-20.33%
2021 S$0.39 B124.82%
2020 S$0.17 B-67.14%
2019 S$0.53 B-11.94%
2018 S$0.61 B185.09%
2017 S$0.21 B-325.82%
2016 -S$95.16 Million-58.12%
2015 -S$0.23 Billion-37.61%
2014 -S$0.37 Billion9.75%
2013 -S$0.34 Billion65.96%
2012 -S$0.2 Billion-291.63%
2011 S$0.10 B-195.59%
2010 -S$0.11 Billion-42.17%
2009 -S$0.19 Billion-18.98%
2008 -S$0.24 Billion-6.99%
2007 -S$0.26 Billion46.3%
2006 -S$0.18 Billion33.25%
2005 -S$0.13 Billion-30.92%
2004 -S$0.19 Billion44.29%
2003 -S$0.13 Billion12.86%
2002 -S$0.12 Billion22.79%
2001 -S$93.02 Million60.14%
2000 -S$58.09 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
S$5.65 B 595.25%๐Ÿ‡ฌ๐Ÿ‡ง UK
S$10.03 B 1,134.83%๐Ÿ‡ซ๐Ÿ‡ท France
S$20.28 B 2,395.89%๐Ÿ‡บ๐Ÿ‡ธ USA
-S$9.33 Billion-1,246.85%๐Ÿ‡บ๐Ÿ‡ธ USA
S$6.34 B 679.96%๐Ÿ‡บ๐Ÿ‡ธ USA
S$24.92 B 2,966.31%๐Ÿ‡บ๐Ÿ‡ธ USA
S$9.40 B 1,057.35%๐Ÿ‡บ๐Ÿ‡ธ USA
-S$60.73 Million-107.47%๐Ÿ‡บ๐Ÿ‡ธ USA
-S$39.36 Million-104.84%๐Ÿ‡บ๐Ÿ‡ธ USA